What is MDEA (MDE)?
MDEA, also known as MDE, 3,4-methylenedioxy-N-ethylamphetamine or Eve, is a synthetic ring-substituted amphetamine related to MDMA and MDA. It differs from MDMA by having an ethyl group rather than a methyl group attached to the terminal nitrogen. The compound is often described as an entactogen or empathogen, although its effects also include stimulant and perceptual changes.
Chemistry and relationship to MDMA
MDEA retains the 3,4-methylenedioxy ring found in MDMA and MDA. The difference lies in the nitrogen substituent: MDEA has an N-ethyl group, MDMA has an N-methyl group, and MDA has no additional alkyl group on the terminal nitrogen. This small structural change affects transporter interactions and metabolism, and it means that findings for MDMA cannot automatically be applied to MDEA.
The compound has one chiral centre and can exist as two enantiomers. As with MDMA, the stereoisomers do not contribute equally to every pharmacological effect. The distinction is relevant when interpreting older studies that used racemic mixtures rather than isolated enantiomers.
Pharmacology
MDEA promotes monoamine signalling, particularly through serotonin release and transporter-mediated effects. Its pharmacology overlaps substantially with MDMA, but historical studies and reviews describe differences in the balance between empathogenic, stimulant and perceptual effects. The available receptor and toxicological literature is reviewed in “The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)”. The methylenedioxy group gives the molecule some mescaline-like properties, while the amphetamine backbone contributes to wakefulness and autonomic stimulation.
MDEA is also metabolized to MDA through N-deethylation. This creates an analytical complication: MDA detected in urine or blood after MDEA exposure may be a metabolite rather than evidence of separate MDA use. Other metabolic pathways include O-demethylenation, catechol methylation and conjugation with sulfate or glucuronic acid.
Human observations and reported effects
MDEA has been examined in human studies, although the research base is much smaller than that for MDMA. A 1992 double-blind, placebo-controlled crossover study in healthy volunteers investigated the effects of MDE on sleep electroencephalography. Other clinical and observational reports describe psychotropic effects broadly similar to MDMA, with feelings of euphoria, emotional openness and sociability. The available studies do not support a precise modern comparison of potency or subjective intensity.
Historical reviews often describe MDEA as less stimulating than MDMA and, in some accounts, more sedating or emotionally subdued. Such distinctions are not consistent enough to define a dependable profile. The compound’s effects vary with the individual, the setting and the material consumed, and older reports often lack modern analytical confirmation.
| Physical and perceptual effects | Cognitive and emotional effects |
|---|---|
|
|
These effects are drawn from a mixture of controlled human observations, older clinical reports and user descriptions. They do not establish that MDEA is simply a milder form of MDMA.
Metabolism and toxicology
A human urine study identified MDEA and its phase I and phase II metabolites after administration, including products formed through N-deethylation and O-demethylenation. The 1996 analytical investigation of MDEA and its metabolites is useful for understanding why MDA can appear after MDEA exposure. N-deethylation produces MDA, while O-demethylenation and subsequent methylation or conjugation generate additional metabolites. These pathways are useful in forensic toxicology, particularly when the parent compound is no longer detectable.
Severe intoxications involving MDEA have been documented, including cases of hyperthermia, cardiovascular complications and fatal poisoning. These reports are uncommon and cannot establish the probability of a particular outcome, but they show that MDEA should not be regarded as harmless because its subjective effects are sometimes described as less stimulating than MDMA. A broad review of the pharmacology and toxicology of MDMA and related compounds is available in “The pharmacology and toxicology of ‘ecstasy’ (MDMA) and related drugs”.
MDEA (MDE) Products
Scientific Data
Identity and Structure
| Chemical Name | MDEA |
|---|---|
| Catalog Entity Type | Compound |
| Formula | C12H17NO2 |
| Molar Mass | 207.273 g·mol−1 |
| CAS | 82801-81-8 |
| CAS Numbers and Substance Forms | 82801-81-8 |
| Synonyms | MDEA; MDE; 3,4-Methylenedioxy-N-ethylamphetamine; N-Ethyl-MDA; Eve; EA-1304; EA1304; PAL-192; PAL192; ASR-1003; ASR1003 |
| IUPAC Name | 1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine |
| SMILES | CCNC(C)Cc1ccc2OCOc2c1 |
Chemical Identifiers
| PubChem CID | 105039 |
|---|---|
| ChemSpider ID | 94775 |
| ChEBI ID | CHEBI:132237 |
| KEGG ID | C22717 |
| UNII | ML1I4KK67B |
| CompTox DTXSID | DTXSID70860971 |
| ECHA ID | 100.231.031 |
Clinical Data
| Drug Class | Serotonin releasing agent; Entactogen |
|---|---|
| Routes of Administration | Oral, insufflation, injection, rectal |
| ATC Code | None |
Pharmacokinetics
| Metabolism | Hepatic including CYP2D6 and CYP3A4 |
|---|---|
| Onset of Action | 20–85 minutes |
| Elimination Half-life | (R)-MDEA: 7.5 ± 2.4 hours (S)-MDEA: 4.2 ± 1.4 hours |
| Duration of Action | 3–5 hours |
| Excretion | Renal |
Legal Status
| Legal Status (Wikipedia Source Text) | AU: S9 (Prohibited substance) BR: Class F2 (Prohibited psychotropics) CA: Schedule I DE: Anlage I (Authorized scientific use only) UK: Class A US: Schedule I UN: Psychotropic Schedule I |
|---|
Sources and Attribution
| Wikipedia Source URL | https://en.wikipedia.org/?curid=23559034 |
|---|